| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.075 | 0.06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.095 | 0.06 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.11 | 0.06 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.23 | 0.06 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.24 | 0.06 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.095 | 0.07 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.07 |